Rice Hall James & Associates LLC decreased its position in shares of Repligen Corp. (NASDAQ:RGEN) by 2.3% during the second quarter, according to its most recent filing with the SEC. The firm owned 73,636 shares of the company’s stock after selling 1,772 shares during the period. Rice Hall James & Associates LLC’s holdings in Repligen Corp. were worth $2,015,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Louisiana State Employees Retirement System boosted its position in Repligen Corp. by 2.1% in the second quarter. Louisiana State Employees Retirement System now owns 14,900 shares of the company’s stock worth $408,000 after buying an additional 300 shares in the last quarter. Legal & General Group Plc boosted its position in Repligen Corp. by 10.2% in the first quarter. Legal & General Group Plc now owns 6,737 shares of the company’s stock worth $184,000 after buying an additional 623 shares in the last quarter. Capstone Asset Management Co. boosted its position in Repligen Corp. by 16.4% in the second quarter. Capstone Asset Management Co. now owns 15,830 shares of the company’s stock worth $433,000 after buying an additional 2,230 shares in the last quarter. BlackRock Group LTD boosted its position in Repligen Corp. by 6.3% in the first quarter. BlackRock Group LTD now owns 49,515 shares of the company’s stock worth $1,328,000 after buying an additional 2,915 shares in the last quarter. Finally, Strs Ohio boosted its position in Repligen Corp. by 9.6% in the second quarter. Strs Ohio now owns 35,400 shares of the company’s stock worth $968,000 after buying an additional 3,100 shares in the last quarter. 89.38% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Repligen Corp. (NASDAQ:RGEN) traded up 2.45% during mid-day trading on Friday, hitting $30.98. The company had a trading volume of 274,956 shares. The firm has a 50-day moving average price of $31.68 and a 200 day moving average price of $27.85. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of 123.92 and a beta of 1.36. Repligen Corp. has a 52-week low of $20.07 and a 52-week high of $36.00.
Repligen Corp. (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, August 4th. The company reported $0.16 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.13 by $0.03. The firm had revenue of $29.20 million for the quarter, compared to analyst estimates of $24.75 million. Repligen Corp. had a net margin of 8.69% and a return on equity of 10.74%. Repligen Corp.’s quarterly revenue was up 35.8% compared to the same quarter last year. During the same period last year, the company posted $0.11 EPS. Analysts expect that Repligen Corp. will post $0.44 earnings per share for the current year.
A number of research firms have recently commented on RGEN. Zacks Investment Research cut Repligen Corp. from a “hold” rating to a “sell” rating in a research note on Saturday, July 30th. Jefferies Group reaffirmed a “hold” rating and set a $28.00 target price on shares of Repligen Corp. in a research note on Monday, June 13th.
In related news, Director Thomas F. Ryan, Jr. sold 2,700 shares of the firm’s stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $32.58, for a total value of $87,966.00. Following the transaction, the director now directly owns 9,394 shares of the company’s stock, valued at approximately $306,056.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.30% of the stock is currently owned by corporate insiders.
Repligen Corp. Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug.
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corp. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corp. and related companies with MarketBeat.com's FREE daily email newsletter.